University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...

The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn ...

ETHealthworld.com brings latest bdr pharma news, views and updates from all top sources for the Indian Health industry.

Baseimmune, a biotechnology company leveraging computational protein design to create next-generation immunotherapies, today unveiled its new fibrosis-focused pipeline, beginning with IPF. IPF is a ...

LONDON--(BUSINESS WIRE)--#IPF--Baseimmune, a biotechnology company leveraging computational protein design to create next-generation immunotherapies, today unveiled its new fibrosis-focused pipeline, ...

Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical ...

Idiopathic pulmonary fibrosis, a rare progressive disease characterized by fibrosis in the alveoli of the lungs, has a median survival of 3 to 5 years if left untreated. Inhaled treprostinil slowed ...

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL ...

“She never wanted anyone to have to naively be in pain without answers," Dern tells PEOPLE of her mother, who died in November 2025 Bailey Richards is a Writer-Reporter at PEOPLE. She has been working ...

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...

Please provide your email address to receive an email when new articles are posted on . Nerandomilast is the first oral preferential phosphodiesterase 4B inhibitor approved for progressive pulmonary ...

Barreling toward the end of its cash runway, GRI Bio has shared phase 2a data in idiopathic pulmonary fibrosis (IPF) and made the case for further development of its potentially disease-modifying ...